Physician profile
Daniel Tucker
NPI 1548316797
$1,960.00
in general payments reported to CMS, 2019-2025
14 companies · $185 in 2025
The $185 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $229 · 2022: $417 · 2023: $715 · 2024: $415 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,306 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,305.90 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $404.67 | 2023-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $374.78 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $371.26 | 2021-2025 | Caplyta |
| Lundbeck LLC | $200.01 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $151.55 | 2023 | Austedo Xr |
| Neurocrine Biosciences, INC. | $122.73 | 2022-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $100.81 | 2022-2024 | Invega Trinza, Invega Sustenna, Spravato |
| Alkermes, INC. | $69.20 | 2021-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $45.72 | 2022-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $41.25 | 2022 | |
| Idorsia Pharmaceuticals US INC | $30.52 | 2022-2023 | Quviviq |
| Tris Pharma INC | $20.45 | 2025 | Dyanavel Xr |
| Indivior INC. | $14.08 | 2023 | Perseris |
| Axsome Therapeutics, INC. | $12.97 | 2023 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Tucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.